DCN and breast carcinoma: Furthermore, the proteoglycan decorin (DCN), which is known to be downregulated in breast cancer and has demonstrated both anti-proliferative and anti-metastatic properties31,51,52, was significantly reduced in late-stage tumours compared to healthy fatpad in our data (Fig. 1e right; C3).